Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

1.

M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma.

Shen L, Li H, Shi Y, Wang D, Gong J, Xun J, Zhou S, Xiang R, Tan X.

Sci Rep. 2016 Jul 28;6:30347. doi: 10.1038/srep30347.

2.

Prediction of survival of diffuse large B-cell lymphoma patients via the expression of three inflammatory genes.

Zhao S, Bai N, Cui J, Xiang R, Li N.

Cancer Med. 2016 Aug;5(8):1950-61. doi: 10.1002/cam4.714. Epub 2016 Jul 9.

3.

Clinical Significance of "Double-hit" and "Double-protein" expression in Primary Gastric B-cell Lymphomas.

He M, Chen K, Li S, Zhang S, Zheng J, Hu X, Gao L, Chen J, Song X, Zhang W, Wang J, Yang J.

J Cancer. 2016 Jun 18;7(10):1215-25. doi: 10.7150/jca.15395. eCollection 2016.

4.

USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma.

Engel K, Rudelius M, Slawska J, Jacobs L, Ahangarian Abhari B, Altmann B, Kurutz J, Rathakrishnan A, Fernández-Sáiz V, Brunner A, Targosz BS, Loewecke F, Gloeckner CJ, Ueffing M, Fulda S, Pfreundschuh M, Trümper L, Klapper W, Keller U, Jost PJ, Rosenwald A, Peschel C, Bassermann F.

EMBO Mol Med. 2016 Aug 1;8(8):851-62. doi: 10.15252/emmm.201506047.

5.

A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma.

Sun J, Cheng L, Shi H, Zhang Z, Zhao H, Wang Z, Zhou M.

Sci Rep. 2016 Jun 13;6:27842. doi: 10.1038/srep27842.

6.

Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.

Beck D, Zobel J, Barber R, Evans S, Lezina L, Allchin RL, Blades M, Elliott R, Lord CJ, Ashworth A, Porter AC, Wagner SD.

J Biol Chem. 2016 Aug 5;291(32):16686-98. doi: 10.1074/jbc.M116.736868. Epub 2016 Jun 6.

PMID:
27268052
7.

Diffuse large B-cell lymphoma of the breast: prognostic factors and treatment outcomes.

Sun Y, Joks M, Xu LM, Chen XL, Qian D, You JQ, Yuan ZY.

Onco Targets Ther. 2016 Apr 6;9:2069-80. doi: 10.2147/OTT.S98566. eCollection 2016.

8.

Anti-Apoptotic Effects of Lentiviral Vector Transduction Promote Increased Rituximab Tolerance in Cancerous B-Cells.

Ranjbar B, Krogh LB, Laursen MB, Primo MN, Marques SC, Dybkær K, Mikkelsen JG.

PLoS One. 2016 Apr 5;11(4):e0153069. doi: 10.1371/journal.pone.0153069. eCollection 2016.

9.

RECQ helicases are deregulated in hematological malignancies in association with a prognostic value.

Viziteu E, Kassambara A, Pasero P, Klein B, Moreaux J.

Biomark Res. 2016 Feb 13;4:3. doi: 10.1186/s40364-016-0057-4. eCollection 2016.

10.

Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.

Ma Y, Zhang P, Gao Y, Fan H, Zhang M, Wu J.

Int J Clin Exp Pathol. 2015 Nov 1;8(11):14875-84. eCollection 2015.

11.

Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.

Chapuy B, Cheng H, Watahiki A, Ducar MD, Tan Y, Chen L, Roemer MG, Ouyang J, Christie AL, Zhang L, Gusenleitner D, Abo RP, Farinha P, von Bonin F, Thorner AR, Sun HH, Gascoyne RD, Pinkus GS, van Hummelen P, Wulf GG, Aster JC, Weinstock DM, Monti S, Rodig SJ, Wang Y, Shipp MA.

Blood. 2016 May 5;127(18):2203-13. doi: 10.1182/blood-2015-09-672352. Epub 2016 Jan 15.

PMID:
26773040
12.

Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas.

Wu R, Nijland M, Rutgers B, Veenstra R, Langendonk M, van der Meeren LE, Kluin PM, Li G, Diepstra A, Chiu JF, van den Berg A, Visser L.

PLoS One. 2016 Jan 11;11(1):e0146624. doi: 10.1371/journal.pone.0146624. eCollection 2016.

13.

CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.

Juilland M, Gonzalez M, Erdmann T, Banz Y, Jevnikar Z, Hailfinger S, Tzankov A, Grau M, Lenz G, Novak U, Thome M.

Blood. 2016 Apr 7;127(14):1780-9. doi: 10.1182/blood-2015-07-655647. Epub 2016 Jan 8.

14.

Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent.

Mondello P, Pitini V, Barresi V, Brea EJ, Di Mirto C, Arrigo C, Cuzzocrea S, Mian M.

Exp Hematol Oncol. 2016 Jan 6;5:1. doi: 10.1186/s40164-015-0030-1. eCollection 2015.

15.

EEPD1 Rescues Stressed Replication Forks and Maintains Genome Stability by Promoting End Resection and Homologous Recombination Repair.

Wu Y, Lee SH, Williamson EA, Reinert BL, Cho JH, Xia F, Jaiswal AS, Srinivasan G, Patel B, Brantley A, Zhou D, Shao L, Pathak R, Hauer-Jensen M, Singh S, Kong K, Wu X, Kim HS, Beissbarth T, Gaedcke J, Burma S, Nickoloff JA, Hromas RA.

PLoS Genet. 2015 Dec 18;11(12):e1005675. doi: 10.1371/journal.pgen.1005675. eCollection 2015 Dec.

16.

Angiomirs expression profiling in diffuse large B-Cell lymphoma.

Borges NM, do Vale Elias M, Fook-Alves VL, Andrade TA, de Conti ML, Macedo MP, Begnami MD, Campos AH, Etto LY, Bortoluzzo AB, Alves AC, Young KH, Colleoni GW.

Oncotarget. 2016 Jan 26;7(4):4806-16. doi: 10.18632/oncotarget.6624.

17.

Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.

Knies N, Alankus B, Weilemann A, Tzankov A, Brunner K, Ruff T, Kremer M, Keller UB, Lenz G, Ruland J.

Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):E7230-8. doi: 10.1073/pnas.1507459112. Epub 2015 Dec 14.

18.

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Camicia R, Winkler HC, Hassa PO.

Mol Cancer. 2015 Dec 11;14:207. doi: 10.1186/s12943-015-0474-2.

19.

Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma.

Wu C, Wu X, Zhang X, Chai Y, Guo Q, Li L, Yue L, Bai J, Wang Z, Zhang L.

Int J Clin Exp Med. 2015 Sep 15;8(9):15173-81. eCollection 2015.

20.

Regulatory network reconstruction reveals genes with prognostic value for chronic lymphocytic leukemia.

Yepes S, Torres MM, López-Kleine L.

BMC Genomics. 2015 Nov 25;16:1002. doi: 10.1186/s12864-015-2189-6.

Items per page

Supplemental Content

Write to the Help Desk